MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$3,963K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
(increase) decrease in prepaid e...
Proceeds from issuance of series...
Fair value of vested stock optio...
Negative Cash Flow Breakdown
Net loss
Increase (decrease) in accounts ...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-4,518
-2,833
-23,031
-3,114
Gain on extinguishment of debt
-
-
-798
0
Stock based compensation
-
46
46
379
Gain on settlement of debt
-
-
798
0
Loss on initial recognition of greenshoe rights liability
-
-
28,736
-
Issuance of warrants for vrt waiver
-
-
0
0
Change in fair value of greenshoe rights liability
-
-
-11,413
-
Fair value of vested stock options
92
-
-
-
Change in fair value of warrant liability
0
-11
3
-232
(increase) decrease in prepaid expenses
-409
-222
-499
-103
Increase (decrease) in accounts payable and accrued expenses
-197
108
1,139
-813
Net cash used in operating activities
-4,260
-2,468
-4,021
-3,677
Exercise of warrants for cash, net
0
577
4,444
0
Proceeds from issuance of series l convertible preferred stock and warrants, net
297
4,003
4,005
1,062
Payment of dividend on series l preferred stock
-
-
144
85
Net cash provided by financing activities
297
4,580
8,305
977
Net increase (decrease) in cash and cash equivalents and restricted cash
-3,963
2,112
4,284
-2,700
Cash and cash equivalents and restricted cash at beginning of period
9,017
6,905
2,621
4,044
Cash and cash equivalents and restricted cash at end of period
5,054
9,017
6,905
2,621
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
series l convertible...
$297K
(-94.54%↓ Y/Y)
Net cash provided by
financing activities
$297K
(-95.43%↓ Y/Y)
Net increase
(decrease) in cash and cash...
-$3,963K
(-410.34%↓ Y/Y)
Canceled cashflow
$297K
(increase) decrease in
prepaid expenses
-$409K
(-281.78%↓ Y/Y)
Fair value of vested
stock options
$92K
Net cash used in
operating activities
-$4,260K
(18.33%↑ Y/Y)
Canceled cashflow
$501K
Net loss
-$4,518K
(-104.53%↓ Y/Y)
Increase (decrease) in
accounts payable and...
-$197K
(87.86%↑ Y/Y)
Buy us a coffee
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)